Total Testosterone Medication-Driven Changes: What Every Lab Result Means

What Is the Normal and Optimal Range for Total Testosterone?

The Endocrine Society's 2018 Clinical Practice Guideline defines the lower limit of the normal male reference interval at 300 ng/dL, based on third-generation mass-spectrometry assays in healthy young men [1]. That floor is a diagnostic line, not a treatment target. Many men feel suboptimal at 310 ng/dL.

For men on testosterone replacement therapy (TRT), most experienced clinicians aim for a mid-normal range of 400 to 700 ng/dL. The Testosterone Trials (TTrials, N=790), published in the New England Journal of Medicine in 2016, titrated injectable and topical testosterone to maintain levels between 500 and 800 ng/dL and demonstrated improvements in sexual function, mood, and bone density at those targets [2].

Reference Ranges by Age

Testosterone declines roughly 1 to 2% per year after age 30 [3]. Lab reference intervals built from mixed-age populations are misleading for younger men. A 35-year-old with a level of 320 ng/dL sits near the population mean for 70-year-olds, not his peers.

The table below summarizes age-stratified reference intervals derived from the Framingham Heart Study subset published in the Journal of Clinical Endocrinology and Metabolism [3]:

| Age group | Mean total T (ng/dL) | 2.5th percentile | |-----------|---------------------|-----------------| | 19 to 39 | 630 | 303 | | 40 to 59 | 520 | 290 | | 60 to 79 | 440 | 220 | | ≥80 | 370 | 190 |

Why "Normal" and "Optimal" Differ

A level within the lab's reference range does not guarantee symptom resolution. The American Urological Association 2022 guideline on testosterone deficiency states that "the goal of testosterone therapy is to raise serum testosterone to the mid-normal range, relieve symptoms, and minimize adverse effects," not simply to clear a threshold [4]. Symptom burden matters as much as the number.

A practical decision framework used by the HealthRX medical team: if a patient reports persistent fatigue, low libido, or loss of lean mass despite a total testosterone above 300 ng/dL, check sex-hormone-binding globulin (SHBG) and calculate free testosterone. Free testosterone below 50 pg/mL in a symptomatic man warrants treatment discussion regardless of total testosterone.

How Testosterone Replacement Therapy Changes the Lab Result

TRT is the most direct and predictable driver of total testosterone values. The route of administration determines both the peak level and the timing of the optimal draw.

Injectable Testosterone (Cypionate and Enanthate)

Testosterone cypionate and enanthate are esterified depot formulations. After a 100 mg intramuscular or subcutaneous injection, total testosterone typically peaks at 48 to 72 hours and troughs just before the next dose. At a standard weekly dose of 100 mg, most men achieve trough levels of 400 to 600 ng/dL and peaks of 800 to 1,100 ng/dL [5].

Drawing at the wrong point in the injection cycle produces wildly different numbers. A trough draw on the day before the next injection in a man on 100 mg weekly cypionate might return 450 ng/dL. A draw 48 hours after the same injection might return 950 ng/dL. Both are correct; neither alone tells the full clinical story.

The Endocrine Society recommends checking a trough level (draw within 24 hours before the next injection) after at least two injection cycles to assess steady-state [1].

Topical Gels and Creams

Testosterone 1.62% transdermal gel (AndroGel) produces steady-state serum levels within 48 to 72 hours of dose initiation. Levels should be checked 2 to 8 hours after application, after at least 14 days of consistent use [1]. Inter-patient absorption variability is high; two men using the same dose can differ by 300 ng/dL at steady state.

Secondary transfer to partners or children is a real risk. The FDA issued a black-box warning on topical testosterone products for this reason [6].

Subcutaneous Pellets

Testosterone pellets (Testopel) are inserted every 3 to 6 months. Levels peak at roughly 4 weeks post-insertion and decline gradually. A single 150 mg pellet raises total testosterone by approximately 100 to 150 ng/dL from baseline. Clinicians typically check levels at 4 weeks to confirm adequate absorption, then at 3 months to assess trough before re-insertion [7].

Oral and Buccal Formulations

Testosterone undecanoate (Jatenzo, oral) and buccal testosterone (Striant) produce more variable serum profiles. Jatenzo achieves steady state within 14 days; lab monitoring is recommended after 14 to 21 days of consistent dosing, with a target of 400 to 700 ng/dL on a sample drawn 6 hours post-dose [6].

Medications That Suppress Total Testosterone

Several drug classes are recognized suppressors of the hypothalamic-pituitary-gonadal (HPG) axis or peripheral testosterone production.

Opioids and Opioid-Induced Androgen Deficiency

Opioid-induced androgen deficiency (OPIAD) is underdiagnosed. Opioids bind mu-receptors in the hypothalamus, suppressing gonadotropin-releasing hormone (GnRH) pulsatility. This reduces LH by up to 86% and testosterone to castrate levels (<100 ng/dL) in some patients [8].

A 2013 study in Pain Medicine (N=80) found that 74% of men on long-term opioid therapy for non-cancer pain had total testosterone levels below 300 ng/dL [8]. Morphine-equivalent daily dose correlated inversely with testosterone (r = -0.61, P<0.001).

All formulations suppress the axis: oral oxycodone, transdermal fentanyl, and buprenorphine. Buprenorphine may suppress the axis less severely than full agonists, but levels still decline meaningfully [9].

Clinicians should screen testosterone in any man on chronic opioids (>90 days), especially at morphine-equivalent doses above 100 mg/day.

Corticosteroids

Glucocorticoids suppress HPG signaling at the hypothalamic and pituitary levels and may also directly inhibit Leydig cell steroidogenesis. Prednisone at ≥20 mg/day for more than 4 weeks reduces total testosterone by 30 to 50% in men [10]. Inhaled corticosteroids at high doses (fluticasone ≥500 mcg/day) produce measurable but smaller suppression, typically 10 to 20%.

A 2012 study in the Journal of Clinical Endocrinology and Metabolism found that men taking oral glucocorticoids had testosterone levels averaging 198 ng/dL compared with 428 ng/dL in age-matched controls [10].

Recovery of the axis after steroid taper is usually complete within 4 to 8 weeks, though this varies with duration and cumulative dose.

GnRH Agonists and Antagonists (Androgen Deprivation Therapy)

GnRH agonists (leuprolide, goserelin) and antagonists (degarelix, relugolix) suppress testosterone to castrate levels (<50 ng/dL) as their therapeutic intent in prostate cancer. These drugs are the most potent pharmacological suppressors of testosterone [11]. Any total testosterone result above 50 ng/dL in a patient on ADT warrants investigation for inadequate suppression or non-adherence.

Ketoconazole and Antifungals

High-dose ketoconazole (400 to 800 mg/day) blocks adrenal and gonadal steroidogenesis by inhibiting CYP11A1 and CYP17A1, reducing testosterone by 50 to 80% within days [12]. This effect was historically used in prostate cancer before dedicated ADT agents became available. Standard dermatological doses (200 mg/day topical or low-dose oral) have minimal systemic testosterone impact.

Spironolactone

Spironolactone blocks androgen receptors and may reduce testosterone synthesis at high doses. In transgender women and in men treated for heart failure or hypertension, doses of 100 to 200 mg/day can reduce free testosterone by 40 to 70% while modestly lowering total testosterone [13].

Statins: A Nuanced Picture

The statin-testosterone relationship is debated. A meta-analysis of 11 randomized trials (N=572) published in PLOS ONE found that statin therapy reduced total testosterone by a mean of 43.5 ng/dL (95% CI: 28.4 to 58.6) compared with placebo [14]. The clinical significance is modest for most men but may matter at borderline-low baseline levels.

Medications That Raise Total Testosterone

Clomiphene Citrate (Clomid)

Clomiphene citrate is a selective estrogen receptor modulator (SERM) that blocks hypothalamic estrogen feedback, increasing GnRH pulsatility and subsequently LH and FSH. In hypogonadal men, 25 to 50 mg every other day raises total testosterone by 100 to 300 ng/dL within 4 to 6 weeks while preserving fertility [15].

A prospective study (N=86) published in the Journal of Urology found that clomiphene raised mean testosterone from 232 ng/dL to 612 ng/dL at 4 to 6 weeks, with 94% of men achieving levels above 300 ng/dL [15]. LH rose from 3.1 to 8.7 mIU/mL in the same cohort.

Monitoring: check total testosterone and LH 4 weeks after initiation or any dose change. Target 400 to 600 ng/dL; supraphysiologic LH (>15 mIU/mL) with high estradiol signals over-stimulation.

Human Chorionic Gonadotropin (hCG)

HCG mimics LH, directly stimulating Leydig cell testosterone production. Used as monotherapy in secondary hypogonadism or as an adjunct to TRT to maintain testicular volume and intratesticular testosterone. Doses of 500 to 1,000 IU subcutaneously two to three times per week raise total testosterone by 150 to 350 ng/dL from baseline [16].

HCG also raises estradiol via aromatization in Leydig cells. Monitoring estradiol alongside testosterone is standard practice when hCG is part of a TRT protocol.

GLP-1 Receptor Agonists (Indirect Effect)

Semaglutide, liraglutide, and tirzepatide do not directly stimulate testosterone production. Their effect is mediated by weight loss. Obesity elevates SHBG and increases aromatase activity in adipose tissue, both of which lower free and total testosterone.

In STEP-1 (N=1,961), semaglutide 2.4 mg produced mean weight loss of 14.9% at 68 weeks versus 2.4% with placebo [17]. Analysis of androgen status in obese hypogonadal men shows that each 10% reduction in body weight raises total testosterone by roughly 60 to 80 ng/dL and free testosterone by 15 to 25% [18].

A 2021 paper in the European Journal of Endocrinology (N=316 obese men) found that weight loss of 10 to 15% normalized testosterone (>300 ng/dL) in 53% of men who had baseline hypogonadism, without any androgen replacement [18]. The effect is dose-dependent on magnitude of fat loss, not on the drug itself.

Anastrozole and Aromatase Inhibitors

Anastrozole inhibits aromatase, reducing the conversion of testosterone to estradiol. This drives LH upward via reduced negative feedback and can raise total testosterone by 50 to 100 ng/dL in men with high baseline estradiol-to-testosterone ratios [19].

Use is controversial. The Endocrine Society notes that aromatase inhibitors are not FDA-approved for male hypogonadism, and their long-term effects on bone density and lipid profiles in men require monitoring [1]. A 2005 NEJM study (N=37) showed anastrozole increased testosterone from a mean of 325 to 434 ng/dL over 12 months in older men with low testosterone and elevated estradiol [19].

Enclomiphene Citrate

Enclomiphene is the trans-isomer of clomiphene with selective ER-antagonist activity at the hypothalamus. Phase 2 data (N=124) published in the International Journal of Andrology showed enclomiphene 12.5 to 25 mg/day raised total testosterone from approximately 220 ng/dL to 430 ng/dL while maintaining sperm counts, compared with TRT which suppressed sperm production in the same trial [20].

Pre-Analytical Variables That Mimic Medication Effects

A medication-free patient can produce results that look drug-driven if the sample is drawn incorrectly.

Timing of Draw

Total testosterone follows a diurnal rhythm. Levels at 08:00 average 20 to 30% higher than at 14:00 in young men. The FDA-cleared assay reference intervals are anchored to morning draws. Afternoon sampling in a non-TRT patient can drop apparent testosterone by 100 to 150 ng/dL and trigger an erroneous hypogonadism diagnosis [1].

Draw between 07:00 and 10:00. For men on daily topical testosterone, draw 2 to 8 hours post-application. For men on weekly injectables, specify trough or mid-cycle and document the timing in the chart.

Biotin Interference

High-dose biotin supplementation (>5 mg/day, common in hair-loss products) interferes with streptavidin-biotin immunoassay platforms and can produce falsely elevated testosterone results. The FDA issued a safety communication on this topic in 2017 [6]. Patients should stop biotin supplementation 48 to 72 hours before testosterone testing.

SHBG Shifts

Medications that raise SHBG (thyroid hormone, estrogen-containing contraceptives, anticonvulsants such as phenytoin) increase total testosterone by binding more of it, while free testosterone remains normal or even falls. Medications that lower SHBG (insulin, glucocorticoids, anabolic steroids, growth hormone) decrease total testosterone on paper while free testosterone may be preserved or even elevated [21].

Always interpret total testosterone alongside SHBG if the clinical picture does not match the number.

Monitoring Intervals by Medication Type

| Medication / context | When to draw first post-change | Steady-state monitoring | |---|---|---| | Injectable TRT (weekly) | 6 to 8 weeks (2 full cycles) | Every 6 to 12 months at stable dose | | Topical gel/cream | 14 to 21 days | Every 6 to 12 months | | Pellets | 4 weeks post-insertion | 3 months (pre-re-insertion trough) | | Clomiphene citrate | 4 to 6 weeks | Every 6 months | | hCG (monotherapy) | 4 to 6 weeks | Every 6 months | | Opioid initiation | 3 months after chronic use established | Annually if continuing opioids | | Oral corticosteroid | 4 weeks on ≥20 mg prednisone/day | With each dose change | | ADT (leuprolide/degarelix) | 3 months after initiation | Every 6 months | | GLP-1 agonist (weight loss) | After 10% body weight reduction | Annually |

Interpreting Results in Women and Non-Binary Patients

Total testosterone reference intervals for cisgender women are 15 to 70 ng/dL by most mass-spectrometry-based assays [1]. Testosterone therapy in transgender men typically targets 400 to 700 ng/dL, mirroring the cisgender male therapeutic range. Monitoring frequency mirrors the TRT schedule for injectable or topical formulations.

In cisgender women, medications such as oral contraceptives raise SHBG by 2 to 4 fold, sharply lowering free testosterone while total testosterone may appear normal or slightly elevated [22]. Danazol and some progestins (norgestrel, levonorgestrel) lower SHBG and can raise both free and total testosterone modestly.

Women with suspected androgen excess (polycystic ovary syndrome, adrenal hyperplasia) should have total testosterone drawn in the early follicular phase (days 2 to 5) of the menstrual cycle where possible, as mid-cycle LH surges transiently raise ovarian androgen output [1].

Key Safety Thresholds and Red Flags

Levels above 1,000 ng/dL in a man on TRT warrant dose reduction. Persistent elevation above 1,200 ng/dL increases erythrocytosis risk; hematocrit above 54% is a threshold for dose interruption per AUA 2022 guidance [4].

Levels below 50 ng/dL in a man not on ADT suggest either extreme HPG suppression (severe opioid use, aggressive steroid dosing, pituitary pathology) or a laboratory error. Repeat the test with a morning fasting specimen and check LH and FSH in the same draw.

A total testosterone above 200 ng/dL in a post-menopausal woman not on androgen therapy should prompt evaluation for an androgen-secreting tumor [1].